GSK PLC-SPON ADR (GSK) Stock Price, Quote, News and Summary
NYSE:GSK - New York Stock Exchange, Inc. - US37733W2044 - ADR
GSK Quote and Key Statistics
GSK PLC-SPON ADR
NYSE:GSK (1/17/2025, 8:05:01 PM)
After market: 33.43 0 (0%)33.43
-0.01 (-0.03%)
GSK Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.83% | ||
| ROA | 6.95% | ||
| ROE | 28.06% | ||
| Debt/Equity | 0.94 |
GSK Performance and Technical Analysis
GSK Ownership and Analysts
GSK Latest News and Analysis
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025.
GSK Enters Agreement to Acquire IDRx, Inc.
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
About GSK
Company Profile
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 70,212 full-time employees. The Company’s segments include Commercial Operations and Research and Development. The company develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. The company is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. The company is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Company Info
GSK PLC-SPON ADR
980 Great West Road
Brentford MIDDLESEX TW8 9GS GB
CEO: Emma Walmsley
Employees: 70212
Company Website: https://www.gsk.com/
Investor Relations: https://www.gsk.com/en-gb/investors/
Phone: 442080475000
GSK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 71.36 | 688.94B | ||
| JNJ | JOHNSON & JOHNSON | 14.36 | 353.99B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 26.86 | 349.49B | ||
| MRK | MERCK & CO. INC. | 16.46 | 247.70B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.48 | 206.53B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.07 | 194.99B | ||
| PFE | PFIZER INC | 10.19 | 149.04B | ||
| SNY | SANOFI-ADR | 12.32 | 127.21B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.11 | 114.17B | ||
| ZTS | ZOETIS INC | 28.8 | 74.84B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.53 | 40.96B | ||
| TEVA | TEVA PHARMACEUTICAL-SP ADR | 7.88 | 24.83B |